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Aims: The pharmacological proﬁle of the novel putative neutral endopeptidase (NEP) and endothelin con-
verting enzyme (ECE) inhibitor SOL1 was examined.
Main methods: The enzyme inhibitory proﬁle of SOL1 was established in vitro. The pharmacokinetic and phar-
macodynamic proﬁle was determined in rodents in vivo.
Key ﬁndings: In vitro, at neutral pH, 10 μM SOL1 inhibited NEP-1, NEP-2, and ECE-1 by 99%, 94% and 75%, respec-
tively. The IC50s were 25, 25 and 3200 nmol/L, respectively. In anesthetized rats, SOL1 inhibited blood pressure
(BP) responses to big-ET-1 and ET-1(1–31) with ED50s of 1.9 and 0.03 mg/kg, corresponding to plasma EC50s of
4.6 and 0.1 μmol/L, respectively. Pharmacokinetics of SOL1 were examined after single injections in mice and
rats. In these species, the estimated clearance of SOL1 varied between 5 and 9 ml/kg.min and T1/2 between 20
and 60min. Steady state kinetics of SOL1 were examined after continuous s.c. infusions of SOL1 for 3 weeks
at 50 mg/kg.day in DOCA-salt hypertensive rats. This treatment lowered BP by 22 mmHg. Steady state concen-
trations of SOL1 in plasma were 3.9 μmol/L. In heart, lung, and kidney the concentrations of SOL1 were 0.4, 1.8,
and 20.5 μmol/kg, respectively. About 63% of the daily dose was retrieved unaltered in the urine.
Signiﬁcance: These data indicate that SOL1 is primarily a NEP inhibitor in vitro as well as in vivo. Given the pref-
erential renal accumulation and renal clearance of SOL1 additional ECE-1 inhibition in the kidneymay have con-
tributed to its chronic BP lowering effects in the DOCA-salt hypertensive rat model.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Endothelin (ET-1) is a pluripotent peptide that affects virtually all
organ systems that regulate blood pressure (BP) and sodium homeo-
stasis (Kohan et al., 2011). Soon after the discovery of ET-1 and its
ETA- and ETB-receptors the potential therapeutic beneﬁt of inhibiting
the ET-axis was proven in several experimental animal models and
clinical trials. ETA/B receptor antagonists have been developed to an-
tagonize ET-1 related effects downstream of its synthesis. While
these receptor antagonists are potentially effective in the treatment
of several cardiovascular diseases, their clinical application is current-
ly limited because of the high incidence of renal side effects leading to
hemodilution and edema formation (Kirkby et al., 2008). This may be
explained by blockade of the ET-1 mediated pro-natriuretic effects.
Recent observations suggest that in addition to ETB receptors also
ETA receptors may mediate sodium excretion (Kohan et al., 2011).
One approach to overcome the side effects of ETA/B receptor blockade
is to further unravel the complexity of the intra-, auto- and paracriney, Maastricht University, PO Box
88134; fax: +31 43 3884149.
B.J.A. Janssen).
-NC-ND license.functions of ET-1. Alternatively, as addressed in the present study,
one may also target the formation of ET-1.
ET-1 can be formed by proteolytic cleavage of its inactive precursor
big-ET-1 (ET-1(1–38)) by endothelin converting enzymes (ECE, Fig. 1).
These metalloproteases are structurally related to neutral endopeptidase
(NEP), an enzyme that converts not only chymase derived ET-1(1–31)
to ET-1 but also degrades well-known vasodilators such atrial natriuretic
peptide (ANP), bradykinin (BK) and calcitonin gene-related peptide
(CGRP). Dual inhibitors of ECE-1 and NEP have been synthesized by a
number of groups (Jeng et al., 2002) with varying selectivity for ECE-1
and NEP. These enzyme inhibitors are less advanced in clinical develop-
ment than ET-receptor antagonists. In preclinical studies dual NEP/ECE in-
hibitors appear not as potent as ETA -antagonists in reducing elevated BP.
Two recent studies (Kalk et al., 2011; Wengenmayer et al., 2011) suggest
that their potential beneﬁt may depend on their ability to alter the bio-
availability of vasoactive peptides in an organ-speciﬁc manner rather
than on their BP-lowering effect (Dhaun and Webb, 2011).
Here we report the pharmacokinetic and pharmacodynamic prop-
erties of a novel dual NEP/ECE inhibitor named SOL1. Our preclinical
studies support the concept that the efﬁcacy of SOL1 depends on
the renal speciﬁc accumulation of the compound and hence varying
local degrees of NEP/ECE inhibition.
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Fig. 1. Schematic overview of the potential role of endothelin (ET-1) converting enzyme (ECE-1) and neutral endopeptidase (NEP) in the synthesis and breakdown of ET-1. Big-ET-1
and ET-1(1–31) were administered in rats to assess the potential of SOL1 to inhibit the contribution of ECE-1 and NEP to the ET-1 induced increase in blood pressure, respectively.
Note that ECE-1 can break down calcitonin gene related peptide (CGRP), while NEP is active against all atrial natriuretic peptide (ANP) and bradykinin (BK), CGRP as well as ET-1.
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Chemicals
Benzazepine acid derivatives are well known NEP inhibitors
(Brands et al., 2006; Jeng et al., 2002). The chemical name of SOL1
is [2-{[1-({[(3S)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-
benzazepin-3-yl]amino}carbonyl)cyclopentyl]methyl}-4-[[3-(methy-
lamino)propyl](methyl)amino]-4-oxobutanoic acid]. The dual NEP/O
O
OH
NN
H
Fig. 2. Structure of SOL1. The chemical name is 2-{[1-({[(3S)-1-(carboxymethyl)-2-oxo
(methylamino)propyl](methyl)amino]-4-oxobutanoic acid. The molecular weight of SOL1 iECE inhibitory proﬁle was obtained by coupling a cyclopentyl group to
benzazepine using a retrosynthetic strategy (Fig. 2). Details of the syn-
thesis of this compound are given in the supplementary data. In the pre-
sent study sodium salt batches of SOL1 were used.
In vitro enzyme inhibition
The enzyme inhibitory proﬁle of SOL1 was determined in vitro
using recombinant sources of NEP and ECE proteins (Innogenetics,N
O
O
N
H
O
O Na
+
-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]amino}carbonyl)cyclopentyl]methyl}-4-[[3-
s 544.6.
Table 1
Potency and selectivity of SOL1 to inhibit the in vitro enzyme activity of the speciﬁed
ECE and NEP enzymes at 10 μM. n=number of observations (in duplicate). IC50 is
the concentration of SOL1 in nM that was needed to inhibit 50% of the enzyme activity.
Enzyme Source n % Inhibition at 10 μM IC50
(nM)
ECE1 Human 3 75 7898±4714
ECE1 Rat (pH 7.0) 2 38 >10.000
ECE1 Rat (pH 5.5) 1 94 251
NEP1 Human 4 99 17±7
NEP2 Human 6 94 34±17
589J. Nelissen et al. / Life Sciences 91 (2012) 587–592Ghent, Belgium). The potency of SOL1 to inhibit these enzymes was
quantiﬁed by measuring the accumulation of a ﬂuorescent big-ET-1
substrate analogue. Experiments were performed at pH7.0. Since
ECE is also located in endosomes (Padilla et al., 2007), and potentially
active in more acidic conditions, inhibition of ECE-1 by SOL1 was also
tested at pH5.5. Concentrations up to 10 μM of SOL1 were used and
the concentration of the inhibitor required to inhibit enzyme activity
by 50% (IC50) was determined. Details of the procedures are provided
in the supplement.
Animals
All animal studies were conducted in accordance with interna-
tional guidelines and approved by the institutional animal care and
use committees of Abbott Pharmaceuticals (Hannover) and the
Maastricht University. Mice and rats were purchased from Charles
River (l'Arbresle, France) or derived from institutional breeding
stocks.
In vivo enzyme inhibition
An arterial and venous line were inserted via the femoral vessels
of ketamine/xylazine anesthetized Sprague-Dawley (SD) rats to en-
able the recording of systolic arterial blood pressure (SBP) and i.v. in-
jections of drugs. Changes in SBP were recorded after i.v. injections of
big-ET-1 (as the ECE substrate) or ET-1(1–31) (as the NEP substrate)
without or with prior administration (5 min. before) of SOL1. The
same tests were performed after intraduodenal administration of
SOL1. Changes in SBP were monitored for twenty minutes after injec-
tion and a blood sample was collected (at ~21 min.) to measure plas-
ma SOL1 concentrations by mass spectrometry (see supplement).
Using these data SOL1 concentrations were estimated at the peak re-
sponse (for big ET-1 at 11 min and for ET-1(1–31) at 8 min) using the
pharmacokinetic properties given below. Finally dose–response
curves were generated and the effective concentration (EC50) and
corresponding effect dose (ED50) of SOL-1 was determined to inhibit
the pressor response by 50%.
In a separate group of rats we measured if SOL1 (30 mg/kg i.v.)
was able to prevent the breakdown of exogenously i.v. applied
CGRP (3 μg/kg) in rats. SOL1 was given 5 min prior to CGRP. Twenty
minutes after administration blood was sampled for CGRP measure-
ments by a commercial radioimmunoassay kit (Phoenix Pharmaceuti-
cals, Burlingame, CA, USA). Data were compared to those obtained in
vehicle treated rats as wells as animals treated with the selective ECE
inhibitor SM-19712 (10 mg/kg).
Pharmacokinetics of SOL1
Pharmacokinetic characteristics of SOL1 were determined in con-
scious SD rats. SOL1 was administered as an i.v. bolus at 1 mg/kg or
given orally at 10 mg/kg. Venous blood samples were collected regu-
larly using the automated Culex® system (Bioanalytical Systems, Inc,
West Lafayette, Indiana, USA) to determine plasma SOL1 concentra-
tions. Data were ﬁtted to a pharmacokinetic non-linear model (PK
WinNonLin model) to derive the clearance rate and the plasma half-
life T1/2. Kinetic parameters of SOL1 were also obtained in male
adult C57BL6 mice after oral (30 mg/kg) or s.c. (30 mg/kg) dosing.
Plasma and organ concentrations of SOL1 were determined in mice
sacriﬁced at 1, 7 and 24 h after SOL1 administration.
Pharmacodynamics of SOL1
Deoxycorticosterone (DOCA)-salt hypertensive male Wistar rats
were chronically treated for 3 weeks with SOL1 (50 mg/kg.day s.c.)
using osmotic minipumps (2ML4, Alzet®, Durect Corporation, Cuper-
tino, CA). Treatment was started at the same time the DOCA (100 mg)pellet was implanted. Details on the rat model and surgical protocols
can be found in the supplement. After 2 weeks of treatment, rats were
maintained in metabolic cages to collect 24-h urine. After 3 weeks of
treatment with SOL1, mean arterial pressure (MAP) was recorded in
conscious unrestrained conditions and compared to values obtained
in vehicle-treated DOCA-salt hypertensive rats. At the end of the
study, SOL1 concentrations were determined in plasma, heart, kidney,
lungs, and urine.
Statistics
Values are presented as means±SEM. In the in vivo inhibition as-
says the effect of varying doses of SOL1 were expressed relatively to
the values obtained in non-treated rats. Maximal inhibitory values
were compared to the non-treated condition using a one-way
analysis of variance (ANOVA). The BP-lowering effect between
SOL1-treated and vehicle-treated DOCA-salt hypertensive rats were
compared by a Student's t-test.
Differences were considered statistically signiﬁcant at P values
b0.05.
Results
The enzyme-inhibitory selectivity of SOL1 is summarized in
Table 1. In vitro and at neutral pH, the compound appeared to be pri-
marily a selective NEP1 inhibitor with an IC50 between 10 and 50 nM
and a maximal inhibitory effect of 90–95%. Inhibition of human ECE1
was observed in the μM range at an efﬁcacy of 75%. The IC50 of SOL1
for rat ECE1 was even lower. However, when the latter assay was per-
formed at pH of 5.5 (as in endosomes) a reasonable IC50 of 250nM
and an inhibitory efﬁcacy of 94% were obtained. In additional in
vitro studies it was established that, at 10 μM, SOL1 did not inhibit
the activities of angiotensin converting enzymes (ACE-1 and ACE-2),
renin, the matrix metalloprotease MMP2, as well as dipeptidypepti-
dase (DPP4, data not shown).
Increasing doses of SOL1 inhibited the rise in SBP in response to
i.v. injections of big-ET-1 or ET-1(1–31) as summarized in Fig. 3.
Full inhibition of the acute rise in SBP in response to big-ET-1 and
ET-1(1–31) was achieved at respective doses of 10 and 0.3 μmol/kg
SOL1. This indicates an in vivo preference of the compound for the
pressor responses to the small NEP substrate ET-1(1–31) over the
larger ECE substrate ET-1(1–38). Plasma SOL1 levels were measured
at the end of the in vivo inhibition assay (collected ~21 min post ad-
ministration). Using the available kinetic information (Fig. 4, supple-
mental data), plasma concentrations of free SOL1 were estimated at
the peak inhibitory response (for big-ET-1 at 11 min; for ET-1(1–31)
at 8 min post administration) and compared to the IC50 concentrations
obtained in vitro (Fig. 3C). From these curveswe determined the in vivo
plasma levels of SOL1 that inhibited the in vivo conversions of big-ET-1
and ET-1(1–31) by 50%. These EC50s averaged 2.6 and 0.044 ng/ml,
respectively and were remarkably different from the observed IC50s
in vitro. The EC50 values for ECE and NEP inhibition correspond to an
i.v. ED50 of 1.9 and 0.03 mg/kg, respectively.
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590 J. Nelissen et al. / Life Sciences 91 (2012) 587–592Both SOL1 (30 mg/kg) and SM-19712 (10 mg/kg) were able to at-
tenuate the breakdown of exogenously applied CGRP. Compared to
plasma levels of CGRP measured in vehicle-treated rats (2.8±
0.4 fmol/l, n=4) CGRP levels after treatment with SOL1 (n=4) and
SM-19712 (n=4) were signiﬁcantly (pb0.05) increased (7.7±0.9
and 4.9±1.0 fmol/l, respectively).
The pharmacokinetic behavior of SOL1 in the plasma of rats and
mice is compared in Fig. 4. After i.v. injection in rats the estimated
T1/2 of SOL1 was 1 h, whereas after oral dosing a T1/2 of 2.5 h was
found. The oral bioavailability of SOL1 was limited to 3%. The volume
of distribution (Vd) of SOL1 was 741 ml/kg. Given the good water sol-
ubility of SOL1 (>500 mg/ml), the Vd is indicative of distribution over0 5 10 15 20 25
0.1
time (hr)
Fig. 4. Average time-dependent changes in plasma SOL1 concentration after intrave-
nous (iv), subcutaneous (sc) or oral dosing in rats and mice. Values are means of 3 ob-
servations in mice and 4 in rats. From these curves, kinetic parameters of SOL1 were
derived using standard modeling programs. These data are presented in more detail
in the supplement.the hydrophilic body compartments. The clearance was estimated at
8.8 ml/min.kg. Comparable clearance rates (~5 ml/kg.min) were de-
rived from the steady state infusion experiments in DOCA-salt hyper-
tensive rats.
In mice, SOL1 plasma and tissue concentrations were determined
at 1, 7, and 24 h after a single bolus injection of the drug. The data
in Fig. 5 indicate that the elimination rate of SOL1 is considerably
slower in the kidney and lungs than in the heart or plasma. Similar
ﬁndings were obtained in steady state conditions during continuous
s.c. infusion of SOL1 for 3 weeks in DOCA-salt hypertensive rats. In
these chronically SOL1-treated DOCA-salt hypertensive rats MAP
was 22 mmHg lower than in vehicle-treated controls (128±6 versus
151±5 mmHg, n=6). In the SOL1- and vehicle-treated rats no dif-
ference was found in 24-h urine volume (79±7 versus 81±9 ml)
and urinary albumin concentrations (4.0±1.5 versus 3.1±
0.7 mg/ml). Circulating concentrations of SOL1 in DOCA-salt hyper-
tensive rats were far above the estimated IC50 level (from the in
vitro studies) needed to inhibit NEP. Renal SOL1 concentrations also
exceeded the estimated IC50 level required to inhibit rat ECE. There-
fore, as summarized in Fig. 5, SOL1 behaves in vivo in the indicated
organs as a NEP inhibitor and in the kidney as a dual NEP/ECEFig. 3. Panel A: in ketamine/xylazine anesthetized Sprague-Dawley rats, the responses
of systolic blood pressure (SBP) to i.v. injections of big endothelin (big ET-1) were
assessed without and after prior administration of increasing doses (1, 3, 10 μmol/kg)
of SOL1. For reasons of clarity statistics are only shown for the peak responses:
* pb0.05, ** pb0.01 compared to vehicle (0 μmol/kg). Panel B: SBP response to ET-
1(1–31) without and after prior administration of increasing doses (0.03, 0.1, 0.3,
1.0 μmol/kg) of SOL1. For reasons of clarity statistics are only shown for the peak re-
sponses: * pb0.05, ** pb0.01 compared to vehicle (0 μmol/kg). Panel C: Comparison
of the in vitro and in vivo inhibitory effects of SOL1. The full and open squares (aver-
age±SEM) indicate the dose-dependent magnitude of enzyme inhibition by SOL1 in
the ET-1(1–31) and big-ET-1 assays. The square and triangle marked in grey mark the
relative inhibition observed after intraduodenal administration of SOL1 (30 μmol/kg).
The in vitro IC50 estimates for the various neutral endopeptidase (NEP) and endothelin
converting enzymes (ECE) (derived from Table 1) are indicated by the thin upward
pointing arrows. SOL1 plasma concentrations were measured at the end of the in vivo
experiments (taken ~21 min post administration) and SOL1 concentrations were
estimated at the peak response (for big ET-1 at 11 min and for ET-1(1–31) at 8 min)
using a PKWinNonLin model. Plasma levels of SOL1 were corrected for free drug concen-
tration (rat FU~96%). Averaged inhibition curves were constructed using a sigmoidal
curve ﬁtting program. From these curves the EC50 of SOL1 to inhibit NEP (dotted down-
ward arrow (a)) and ECE (dotted downward arrow (b)) were derived. These values
were 44 ng/ml for NEP and 2.6 μg/ml for ECE. These values correspond to an i.v. ED50 of
0.03 and 1.9 mg/kg, respectively.
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Fig. 5. Plasma and tissues concentrations of SOL1 after an acute (subcutaneous) s.c.
30 mg/kg dose of SOL1 in mice (panel A) and after 3 weeks of chronic s.c. infusion of
50 mg/kg s.c. in DOCA-salt hypertensive rats (panel B). In mice, SOL1 was rapidly
cleared from the plasma and heart and concentrations fell below EC50 levels for ECE
in lung and heart after 7 h of administration. After chronic infusion in DOCA-salt hyper-
tensive rats, the highest concentrations of SOL1 were found in the kidney being well
above the estimated EC50 for ECE-inhibition. * pb0.05 compared to plasma values.
591J. Nelissen et al. / Life Sciences 91 (2012) 587–592inhibitor. In the chronic dosing study, 63% of the infused amount of
SOL1 was retrieved in an unaltered form in the urine. These data indi-
cate that SOL1 excretion is predominantly renal.Discussion
Here we report the synthesis and pharmacokinetic and pharmaco-
dynamic properties of the novel dual NEP/ECE inhibitor SOL1. Using a
retrosynthetic strategy, SOL1 was synthesized by the coupling of
commercially available cyclopentyl and benzazepine building blocks.
In vitro and at neutral pH, SOL1 acted as a potent NEP inhibitor but a
rather weak ECE inhibitor with IC50's of 17–34 nM and 7–10 μM, re-
spectively. SOL1 did not inhibit the activity of any of the indicated
proteases. This in vitro proﬁle is comparable to the one reported for
phosphoramidon. The latter compound has been widely used both
in vitro and in vivo as a non-selective NEP/ECE inhibitor (IC50 for
NEP 4–30 nM; IC50 for ECE 1–4 μM) (Brands et al., 2006; Jeng et al.,
2002). It should be noted that these IC50 values are based on the use
of recombinant enzymes in cell free conditions. In living organisms,
NEP and ECE are membrane bound. Thus the in vivo inhibitory effects
of such putative inhibitors also depend on their ability to reach these
targets in a sufﬁciently high concentration. We found that SOL1 is
highly water soluble (>500 mg/ml) and that its volume of distribu-
tion is about 0.7 L/kg. These values are suggestive for a distribution
of the drug over the full water compartment of the body.
Despite weak in vitro inhibitory effects on ECE, the in vivo potency
of SOL1 against the big-ET-1-induced pressor response was quite re-
markable. Following i.v. administration, SOL1 fully blocked the big-
ET-1-induced rise in BP at a dose of 10 μmol/kg. The estimated ED50
of SOL1 was 1.9 mg/kg. This dose is comparable to those reportedfor the more selective ECE inhibitor SM-19712 (10 mg/kg i.v.) or
indole-based compounds (3 mg/kg i.v.) (Brands et al., 2006). As indi-
cated in Fig. 3c, the in vivo EC50 of SOL1 for rat-ECE is shifted by about
1 log scale to the left when compared to the in vitro IC50 estimate. In
contrast, the in vivo EC50 for NEP inhibition was considerably higher
than the in vitro estimates. These data suggest that the conversion
of substrates by ECE and NEP may have quite a different in vivo efﬁ-
cacy. We attempted to quantify the in vivo ECE-inhibitory component
of SOL1 by comparing big-ET-1 levels in the plasma of SOL1-treated
and vehicle-treated DOCA-salt rats. Unfortunately, a conclusion
could not be drawn because the levels of the peptide were below
the detection limit. On the other hand, we could establish that SOL1
attenuated the clearance of exogenously applied CGRP to rats in a
similar fashion as the selective ECE inhibitor SM-19712. Cumulatively
these data suggest that SOL1, like phosphoramidon, does exhibit ECE-
inhibitory effects in vivo, certainly at doses>10 mg/kg, and that its
effects are not entirely NEP mediated.
As previously reported by Corder and Vane, exogenously applied
big-ET-1 is rapidly cleared from the circulation (Corder and Vane,
1995). If conversion of big-ET-1 occurs mainly at the luminal site of
the endothelium, then injections of big-ET-1 would be accompanied
by ETB-mediated acute depressor responses, as is the case for intrave-
nously administered ET-1. These are generally not observed. Most of
the evidence thus far suggests that big-ET-1 is converted to ET-1 in
the sub-endothelial matrix or at the plasma membrane of vascular
smooth muscle cells (Corder and Vane, 1995; Hisaki et al., 1993).
More recent observations showed that ECE located at plasma mem-
branes can be internalized to intracellular endosomes. The ECE-
dependent breakdown of CGRP occurred in these organelles more ef-
fective at acidiﬁed (pH 5.5) than at neutral pH (7.4) (Padilla et al.,
2007). These ﬁndings strengthen the possibility that despite its
water-soluble characteristics, SOL1 together with ECE is internalized
and inhibits the conversion of substrates more effectively at these lo-
cations than in the blood compartment. Clearly more work is needed
to unravel the precise molecular mechanisms of action of such
inhibitors.
From the pharmacokinetic studies, in both rats and mice, it
appeared that SOL1 was rapidly cleared from the plasma. However,
in the lungs and especially in the kidneys concentrations of SOL1
remained signiﬁcantly higher than those found in plasma, both after
a single administration in mice as well as during steady state condi-
tions in rats. The preference of SOL1 to accumulate in these organs
may be due to its binding to abundantly present NEP and ECE en-
zymes in these tissues (Goldie et al., 1996; Kohan et al., 2011). Alter-
natively, high renal concentrations may be due to the speciﬁc
elimination pathway of the drug. In steady state conditions in rats,
63% of the daily infused amount of SOL1 was recovered in the urine.
The renal concentration of SOL1 was sufﬁciently high to inhibit, be-
sides NEP also ECE in this organ. Given the important role of ET-1 in
renal sodium excretion (Kohan et al., 2011), additional ECE inhibition
may have contributed to the chronic BP-lowering effect of SOL1 in
DOCA-salt hypertensive rats. The present study was not designed to
test the underlying mechanisms in detail. Because SOL1 is also a po-
tent NEP inhibitor, the accumulation of endogenous vasoactive pep-
tides like ANP, BK, and CGRP that are catalyzed by NEP may have
also contributed to the BP lowering effect. Since C-ﬁber-derived pep-
tides such as CGRP may be downregulated in salt-sensitive models of
hypertension (Wang and Zhao, 2003) and CGRP selectively termi-
nates the long-lasting binding of ET-1 to the ETA receptor (Meens et
al., 2010, 2011) we hypothesize that the accumulation of this partic-
ular peptide may play a crucial role in mediating the antihypertensive
effects of SOL1 in this model. These aspects are currently under inves-
tigation (Nelissen et al., 2011).
In the present study SOL1 did not inﬂuence renal albumin excre-
tion. This may be due to the fact that the extent of renal damage is
still limited after 2 weeks of DOCA- salt treatment. In other rat models
592 J. Nelissen et al. / Life Sciences 91 (2012) 587–592beneﬁcial effects of combined NEP/ECE inhibitors may occur indepen-
dent of their BP-lowering effects. The dual NEP/ECE inhibitor SLV338
reduced renal damage in chronically L-NAME-treated rats and pre-
served kidney function and reduced mortality in a rat model of severe
acute renal failure (Sharkovska et al., 2011). SLV338 also prevented
interstitial and perivascular ﬁbrosis in the heart (Kalk et al., 2011)
of 2-kidney 1-clip rats and reduced the incidence of stroke
(Wengenmayer et al., 2011) in a BP-independent manner. These
data strengthen the concept presented in this paper that the effects
of NEP/ECE inhibition may vary throughout the body. Although
NEP/ECE inhibitors are not potent BP-lowering agents, organ speciﬁc
enzyme inhibition may add to their beneﬁcial effect. As proposed re-
cently, (Dhaun and Webb, 2011), the clinical potential of such NEP/
ECE inhibitors should therefore not be judged only by their antihyper-
tensive potential but should be reevaluated taking functional organ-
speciﬁc parameters into account. The current dual NEP/ECE efﬁcacy
of SOL1 in renal tissue may make this drug applicable in conditions
of chronic renal failure.Conﬂict of interest statement
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